慢性 骨髄 単 球 性 白血病。 [mixi]ハイドレアという薬をご存じでしょうか?

Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels : the JALSG CML202 study. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Molecular monitoring in CML and the prospects for treatment-free remissions. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia : the ANAHYDRET Study, a randomized controlled trial. NCCN clinical practice guideline in oncology. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, IARC ; 2017 : pp16-27. Hematology Am Soc Hematol Educ Program. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008 : a population-based study. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. Final 5-year study results of DASISION : The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chro-mosome-positive leukemias treated with bosutinib. Polycythemia vera : scientific advances and current practice. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues ed. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase : 5-year update of the randomized ENESTnd trial. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. Ismael O, Shimada A, Hama A, et al. Essential thrombocythemia beyond the first decade : life expectancy, long-term complication rates, and prognostic factors. DIPSS plus : a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Chronic myeloid leukemia : an update of concepts and management recommendations of European LeukemiaNet. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Long-term follow-up of 386 consecutive patients with essential thrombocythemia : safety of cytoreductive therapy. Introduction and overview of the classification of myeloid neoplasms. Long term outcomes of imatinib treatment for chronic myeloid leukemia. European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. Chronic myeloid leukaema, BCR-ABL1-positive. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. Clinical features and outcomes of patients with primary myelofibrosis in Japan : report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, IARC ; 2017 : pp30-6. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. No treatment for low-risk thrombocythaemia : results from a prospective study. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of highrisk, Philadelphia-positive chronic myeloid leukemia : a European LeukemiaNet Study. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment : the EUTOS score. Chronic myeloid leukemia Version 3. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis : a report on 14 patients. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. A prognostic model to predict survival in 867 World Health Organization-defined essential hrombocythemia at diagnosis : a study by the International Working Group on Myelofibrosis Research and Treatment. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Standardized definitions of molecular response in chronic myeloid leukemia. Shiba N, Hasegawa D, Park MJ, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Pérez B, Kosmider O, Cassinat B, et al. The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia : retrospective analysis of 39 patients in Japan. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : results from the BELA trial. Writing Committee for the Collaborative CML Prognostic Factors Project Group.。 。 。

2

19

。 。

。 。

19

2

。 。 。

5

。 。 。

2

9